- Exploring efficiencies from eTMF with Cancer Research UK
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
resTORbio reports interim data from Parkinson’s trial
resTORbio has reported positive interim findings from three cohorts in the Phase Ib/II clinical trial of RTB101 in patients with Parkinson’s disease.
New clinical trial firm Curavit Clinical Research officially launches
A new clinical trials company, Curavit Clinical Research, has been launched to help realise the potential of decentralised clinical trials.
Teva’s deutetrabenazine fails in paediatric Tourette syndrome trials
Results from Teva Pharmaceutical Industries have revealed that deutetrabenazine did not meet the primary endpoint in Phase II/III ARTISTS 1 and Phase III ARTISTS 2 studies involving pediatric patients with moderate to severe Tourette syndrome.
Serum Institute of India brings Covid-19 vaccine into animal testing
Serum Institute of India has announced that its new Covid-19 vaccine candidate, being developed in collaboration with US-based Codagenix, is now in pre-clinical / animal testing phase.
IBM Watson launches Cloud-based tool for clinical trials optimisation
IBM Watson Health has launched its latest Cloud-based technology, IBM Study Advance, which has been designed to reduce the cost and time associated with clinical trials.
Zelira reports positive data from cannabis trial in insomnia
Australia-based Zelira Therapeutics has reported positive results from the Phase Ib/IIa clinical trial of cannabis drug candidate ZLT-101 in patients with chronic insomnia.
Five Prime Therapeutics’ pancreatic cancer combo misses endpoint
Five Prime Therapeutics has reported that the Phase II clinical trial of its cabiralizumab (FPA008) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) missed the primary endpoint in advanced pancreatic cancer patients.
Alnylam closes enrolment in Phase III trial of vutrisiran
Alnylam Pharmaceuticals has completed patient enrolment in the Phase III HELIOS-A clinical trial of vutrisiran for the treatment of hereditary transthyretin (hATTR) amyloidosis.